- Home
- SPNS vs AKRO Comparison
SPNS vs AKRO Comparison
Compare SPNS & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPNS
- AKRO
- Stock Information
- Founded
- SPNS 1982
- AKRO 2017
- Country
- SPNS Israel
- AKRO United States
- Employees
- SPNS N/A
- AKRO N/A
- Industry
- SPNS Computer Software: Prepackaged Software
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- SPNS Technology
- AKRO Health Care
- Exchange
- SPNS Nasdaq
- AKRO Nasdaq
- Market Cap
- SPNS 1.6B
- AKRO 3.9B
- IPO Year
- SPNS 1992
- AKRO 2019
- Fundamental
- Price
- SPNS $29.51
- AKRO $51.69
- Analyst Decision
- SPNS Buy
- AKRO Strong Buy
- Analyst Count
- SPNS 4
- AKRO 6
- Target Price
- SPNS $34.25
- AKRO $82.50
- AVG Volume (30 Days)
- SPNS 159.8K
- AKRO 1.6M
- Earning Date
- SPNS 07-31-2025
- AKRO 08-08-2025
- Dividend Yield
- SPNS 2.03%
- AKRO N/A
- EPS Growth
- SPNS 11.11
- AKRO N/A
- EPS
- SPNS 1.30
- AKRO N/A
- Revenue
- SPNS $544,235,000.00
- AKRO N/A
- Revenue This Year
- SPNS $8.30
- AKRO N/A
- Revenue Next Year
- SPNS $7.42
- AKRO N/A
- P/E Ratio
- SPNS $23.09
- AKRO N/A
- Revenue Growth
- SPNS 3.84
- AKRO N/A
- 52 Week Low
- SPNS $23.69
- AKRO $21.34
- 52 Week High
- SPNS $41.22
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- SPNS 53.39
- AKRO 45.35
- Support Level
- SPNS $29.50
- AKRO $50.13
- Resistance Level
- SPNS $30.54
- AKRO $53.60
- Average True Range (ATR)
- SPNS 0.51
- AKRO 2.03
- MACD
- SPNS 0.05
- AKRO -0.83
- Stochastic Oscillator
- SPNS 57.26
- AKRO 6.37
About SPNS Sapiens International Corporation N.V. (Cayman Islands)
Sapiens International Corp NV is a provider of software solutions for the insurance industry, with an emerging focus on the financial services sector. The company offers software, solutions, and professional services for property & casualty (P&C); reinsurance; life, pension & annuity (L&A); workers' compensation (WC); medical professional liability (MPL); financial & compliance (F&C); and decision modeling for both insurance and financial markets. The group also provides services for project delivery and implementation services, for its Software Solutions portfolio. Geographically, it operates in the region of North America, Rest of the World, and Europe. It generates revenue from Europe.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.